Techniclone borrows money to buy time as problems crowd in
This article was originally published in Clinica
Financially troubled Techniclone has announced a string of further bad news. Its chairman of one month's standing has resigned, it has defaulted on a $3.3 million loan and its stock is threatened with a delisting from NASDAQ. Techniclone has borrowed money from investors to continue operations at reduced levels. In addition, a clinical trial into Oncolym, a direct tumour targeting agent, has been cancelled.
You may also be interested in...
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.